Jacob D Soumerai
Overview
Explore the profile of Jacob D Soumerai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
1013
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Ababneh H, Ng A, Abramson J, Soumerai J, Takvorian R, Frigault M, et al.
Hematol Oncol
. 2023 Oct;
42(1):e3231.
PMID: 37795759
CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment for patients with relapsed/refractory large B-cell lymphoma (LBCL). However, data available concerning the impact of the prognostic value of quantitative...
12.
Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial
Neilan T, Quinaglia T, Onoue T, Mahmood S, Drobni Z, Gilman H, et al.
JAMA
. 2023 Aug;
330(6):528-536.
PMID: 37552303
Importance: Anthracyclines treat a broad range of cancers. Basic and retrospective clinical data have suggested that use of atorvastatin may be associated with a reduction in cardiac dysfunction due to...
13.
Karschnia P, Arrillaga-Romany I, Eichler A, Forst D, Gerstner E, Jordan J, et al.
Neuro Oncol
. 2023 Jul;
25(12):2239-2249.
PMID: 37402650
Background: Chimeric antigen receptor (CAR) T-cells targeting CD19 have been established as a leading engineered T-cell therapy for B-cell lymphomas; however, data for patients with central nervous system (CNS) involvement...
14.
Bantilan K, Kay N, Parikh S, Rabe K, Call T, Leis J, et al.
Leuk Lymphoma
. 2022 Dec;
64(2):300-311.
PMID: 36503412
Targeted therapies have largely replaced chemoimmunotherapy (CIT) in first-line treatment of chronic lymphocytic leukemia (CLL). We aimed to develop a prognostic model to determine who would benefit from first-line CIT...
15.
Miller K, Johnson P, Abramson J, Soumerai J, Yee A, Branagan A, et al.
Blood Cancer J
. 2022 Nov;
12(10):146.
PMID: 36316312
Chimeric antigen receptor T cells (CAR T) are groundbreaking therapies but may cause significant toxicities including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and cytopenias. Granulocyte colony-stimulating...
16.
Soumerai J, Takvorian R, Sohani A, Abramson J, Ferry J
Lancet Haematol
. 2022 Sep;
9(10):e796.
PMID: 36174642
No abstract available.
17.
18.
Roeker L, Feldman T, Soumerai J, Falco V, Panton G, Dorsey C, et al.
Clin Cancer Res
. 2022 Jul;
28(18):3958-3964.
PMID: 35852793
Purpose: Ibrutinib has transformed the management of chronic lymphocytic leukemia (CLL), though its use is limited by toxicity and resistance. In this study, we utilized an "add on" approach for...
19.
Pagel J, Soumerai J, Reddy N, Jagadeesh D, Stathis A, Asch A, et al.
Lancet Oncol
. 2022 Jul;
23(8):1021-1030.
PMID: 35835137
Background: Phosphatidylinositol 3-kinase p110δ (PI3Kδ) inhibitors are efficacious in B-cell malignancies. Immune-related adverse events might be mitigated with intermittent dosing. We aimed to evaluate the safety and antitumour activity of...
20.
Soumerai J, Rosenthal A, Harkins S, Duffy J, Mecca C, Wang Y, et al.
Blood
. 2022 Jul;
140(16):1822-1826.
PMID: 35802834
No abstract available.